High USP22 expression indicates poor prognosis in hepatocellular carcinoma.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 4494964)

Published in Oncotarget on May 20, 2015

Authors

Bo Tang1,2, Fang Tang3, Bo Li1,2, Shengguang Yuan1,2, Qing Xu1,2, Stephen Tomlinson4, Junfei Jin2, Wei Hu5, Songqing He1,2

Author Affiliations

1: Department of Hepatobiliary Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.
2: Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, Guilin, Guangxi, People's Republic of China.
3: Department of Pathology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.
4: Department of Microbiology and Immunology, Darby Children's Research Institute, Medical University of South Carolina, Charleston, South Carolina, USA.
5: Department of Laboratory Medicine, The First Hospital of Jilin University, Changchun, Jilin, People's Republic of China.

Articles cited by this

Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22

Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31

Primary liver cancer: worldwide incidence and trends. Gastroenterology (2004) 11.21

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell (2008) 3.42

Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol (2006) 2.17

A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer (2010) 1.46

USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle (2008) 1.34

Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res (2008) 1.33

The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns (2005) 1.30

CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res (2012) 1.23

USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep (2011) 1.17

USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys (2012) 1.12

Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol (2010) 1.11

Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol (2011) 1.08

The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma. Cell Biochem Biophys (2011) 0.96

USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol (2012) 0.95

Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. Eur J Histochem (2012) 0.95

USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma. PLoS One (2012) 0.92

Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas. Diagn Mol Pathol (2010) 0.88

Ginsenoside Rb1 attenuates oxygen-glucose deprivation-induced apoptosis in SH-SY5Y cells via protection of mitochondria and inhibition of AIF and cytochrome c release. Molecules (2013) 0.88

Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma. Oral Oncol (2013) 0.86

Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma. Ann Hepatol (2012) 0.84